198 related articles for article (PubMed ID: 17289801)
1. MESOMARK: a potential test for malignant pleural mesothelioma.
Beyer HL; Geschwindt RD; Glover CL; Tran L; Hellstrom I; Hellstrom KE; Miller MC; Verch T; Allard WJ; Pass HI; Sardesai NY
Clin Chem; 2007 Apr; 53(4):666-72. PubMed ID: 17289801
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
Di Serio F; Fontana A; Loizzi M; Capotorto G; Maggiolini P; Mera E; Bisceglia L; Molinini R
Clin Chem Lab Med; 2007; 45(5):634-8. PubMed ID: 17484626
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
9. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
10. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
Weber DG; Taeger D; Pesch B; Kraus T; Brüning T; Johnen G
Cancer Biomark; 2007; 3(6):287-92. PubMed ID: 18048966
[TBL] [Abstract][Full Text] [Related]
11. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
13. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
14. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
15. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
Franko A; Dolzan V; Kovac V; Arneric N; Dodic-Fikfak M
Dis Markers; 2012; 32(2):123-31. PubMed ID: 22377706
[TBL] [Abstract][Full Text] [Related]
16. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
17. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
[TBL] [Abstract][Full Text] [Related]
19. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP
J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141
[TBL] [Abstract][Full Text] [Related]
20. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]